Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 6,763 matching trials from the live ClinicalTrials.gov search.
Filters: Bethesda, Maryland Clear all
Completed No phase listed Observational Accepts healthy volunteers

Mapping the Areas of the Brain Associated With Language in Children With Epilepsy

NCT00001366
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 7:18 PM EDT
Completed Phase 1 Interventional

Pilot Study of Laser Photocoagulation Therapy for Diabetic Macular Edema

NCT00069056
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Laser Treatment
Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 7:18 PM EDT
Completed Phase 1 Interventional

Twins Study of Gene Therapy for HIV Infection

NCT00001535
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infection, Kaposi's Sarcoma
Interventions
Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2008 · Synced Oct 22, 2026, 7:18 PM EDT
Completed Phase 1 Interventional

Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas

NCT01794104
View directory record Official record
Conditions
Neoplasm, Lymphoma
Interventions
LMP400
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 22, 2026, 7:18 PM EDT
Terminated Not applicable Interventional Results available

Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)

NCT05093504
View directory record Official record
Conditions
Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative
Interventions
Sham comparator, DrugSorb-ATR system
Device
Lead sponsor
CytoSorbents, Inc
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
27
States / cities
Sacramento, California • Denver, Colorado • New Haven, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 22, 2026, 7:18 PM EDT
Recruiting Phase 3 Interventional

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

NCT05727904
View directory record Official record
Conditions
Metastatic Melanoma, Unresectable Melanoma, Melanoma
Interventions
Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
24
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Recruiting No phase listed Observational

Apheresis of Patients With Immunodeficiency

NCT01212055
View directory record Official record
Conditions
LAD-1, DOCK8, GATA2 Deficancy
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 40 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Active, not recruiting No phase listed Observational

NIH-AARP Diet and Health Secondary Research Study Based on OH95CN025 Data

NCT04750915
View directory record Official record
Conditions
Cancer, Mortality, Chronic Diseases
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
50 Years to 71 Years
Enrollment
566,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2050
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Completed No phase listed Observational

Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

NCT00897325
View directory record Official record
Conditions
Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Non-Hodgkin Lymphoma
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
168
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 22, 2026, 7:18 PM EDT
Completed No phase listed Observational

Study of Megakaryocytes From Patients With Abnormal Platelet Vesicles

NCT00086476
View directory record Official record
Conditions
Blood Coagulation Disorders
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 7:18 PM EDT
Terminated Phase 1Phase 2 Interventional

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma

NCT00003552
View directory record Official record
Conditions
Stage IV Melanoma, Recurrent Melanoma
Interventions
allogeneic lymphocytes, anti-thymocyte globulin, cyclophosphamide, fludarabine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 60 Years
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 22, 2026, 7:18 PM EDT
Completed No phase listed Observational

Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00482352
View directory record Official record
Conditions
Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
11,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2023
U.S. locations
176
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 22, 2026, 7:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

AMI Construction in Lower Extremity Residual Limbs

NCT04063592
View directory record Official record
Conditions
Amputation
Interventions
Residual limb revision
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
3
States / cities
Bethesda, Maryland • Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Terminated No phase listed Observational

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

NCT04982471
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
53
States / cities
Hot Springs, Arkansas • Boulder, Colorado • Pensacola, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 22, 2026, 7:18 PM EDT
Completed Phase 2 Interventional

Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00079144
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
NY-ESO-1 peptide vaccine, aldesleukin, filgrastim, incomplete Freund's adjuvant, therapeutic autologous lymphocytes, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 22, 2026, 7:18 PM EDT
Recruiting Phase 1 Interventional

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

NCT04902443
View directory record Official record
Conditions
Viral Associated Malignancies, Kaposi Sarcoma, EBV/KSHV-associated Lymphomas
Interventions
Pomalidomide, Nivolumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Central Mechanisms in Speech Motor Control Studied With H215O PET

NCT00001308
View directory record Official record
Conditions
Communication Disorder, Healthy, Stuttering, Tourette Syndrome, Voice Disorder
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years to 85 Years
Enrollment
1,163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 22, 2026, 7:18 PM EDT
Recruiting Phase 2 Interventional

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

NCT06511908
View directory record Official record
Conditions
Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action, Neurotransmitter Agents, Excitatory Amino Acid Agents, Physiological Effects of Drugs, Depressive Disorder, Major, Depressive Disorder, Depression, Mental Disorders, Mood Disorders, Behavioral Symptoms
Interventions
(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg), Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Withdrawn Phase 2 Interventional

Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B

NCT03575208
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
hepatitis B immune globulin (HBIg), Pegylated interferon alfa (pegIFN)
Biological · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 22, 2026, 7:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers

NCT00001284
View directory record Official record
Conditions
Genotype, Allelic Frequencies of Genetic Markers, Brain Mapping, Brain Disease, fMRI
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
2,802 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 22, 2026, 7:18 PM EDT
Terminated Phase 2 Interventional Results available

Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

NCT02227108
View directory record Official record
Conditions
B-Cell Pediatric ALL
Interventions
Moxetumomab Pasudotox
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 18 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 22, 2026, 7:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ischemic Nerve Block to Improve Hand Function in Stroke Patients

NCT00056706
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
Transient deafferentation
Procedure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 7:18 PM EDT
Completed No phase listed Observational Results available

A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors

NCT01131104
View directory record Official record
Conditions
Nonarteritic Anterior Ischemic Optic Neuropathy
Interventions
PDE5 Inhibitors
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
44
States / cities
Birmingham, Alabama • Los Altos, California • National City, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 22, 2026, 7:18 PM EDT
Active, not recruiting Phase 1 Interventional

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

NCT02203526
View directory record Official record
Conditions
Primary Central Nervous System Lymphoma
Interventions
Isavuconazole, TEDDI, Rituximab, Cytarabine, TEDD, Ibrutinib (Arms 2, 3 and 4), Methotrexate, Ibrutinib (Arm 1 - Closed with Amendment G), Ibrutinib (Arm 4)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 7:18 PM EDT